Literature DB >> 33992690

Potential future implications of the COVID-19 pandemic on Norovirus infections in England.

M Hotham1.   

Abstract

Entities:  

Year:  2021        PMID: 33992690      PMCID: PMC8116312          DOI: 10.1016/j.jinf.2021.05.003

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear Editor, I read with interest the recent article by Eigner et al., in the Journal of infection, highlighting the reduction in Norovirus (NoV) infections reported in Germany since the introduction of COVID-19 containment measures in 2020. In the UK, there has been a reduction in both NoV infections and outbreaks reported to Public Health England (PHE) since the introduction of Nonpharmaceutical Interventions (NPIs) by the UK government to contain the COVID-19 pandemic in March 2020. The GII.4 NoV strain was detected in the mid-20th century and has undergone evolution in the form of 7 new variants since the 1990s which have been associated with global epidemics. These have appeared on average every 2–3 years, but a new variant has not been detected since ‘The Sydney strain’ in 2012. There are concerns about the potential for an undetected new strain shift, as a result of the reduced surveillance over the last year. PHE surveillance data on NoV is collected via four main sources. The Second-Generation Surveillance System (SGSS) records all positive norovirus tests reported to labs in England. The Hospital Norovirus Outbreak Reporting System (HNORS) includes online reporting of both confirmed and suspected hospital outbreaks of norovirus across England. HPZone is used by Health Protection Teams (HPTs) to record suspected and confirmed enteric virus (EV) outbreaks notified to them. The Enteric Virus Unit monitors genotype and characterisation of NoV nationally. Data is collected across the ‘Norovirus season’ which runs from week 27 (July) in year 1 to week 26 (June) in year 2, in order to capture the winter peak of activity. PHE surveillance data since week 12 of the 2019/2020 season through to the 2020/2021 season have shown markedly reduced levels of norovirus positive tests and EV outbreaks reported compared with the 5-season average. The cumulative total of EV reports in the 2020/2021 season to week 7 is 89% lower than the 5-season average. It is hard to argue that the NPIs introduced to contain COVID-19 have not had a significant impact on the transmission of NoV. However, this must be interpretated with caution. The underreporting of enteric virus cases is an issue that will only have worsened during the pandemic, due to factors such as reduced access to NHS services and the impact on testing capacity. Douglas et al., discussed the reduction in the referral of NoV-positive samples in the UK for characterisation and genotyping during the pandemic in the Journal of hospital infection. They suggest that such a significant reduction could result in key indicators for NoV strain replacement events being missed. With UK COVID containment measures set to ease, the authors warn of the ongoing risk to healthcare services due to the potential occurrence of a new NoV strain in a population with low levels of immunity. There have been reports of increasing numbers of NoV outbreaks across China since the easing of COVID-19 restrictions there. This highlights the reality of the risk of significant NoV outbreaks occurring to a greater degree once containment measures are lifted. It is clear to see that, despite factors leading to underreporting of surveillance data, there has been a substantial impact on NoV infections due to COVID-19 containment measures implemented both in the UK and globally. What is not clear is what the implications of this may be for the future. There remains the possibility for the emergence of new NoV strains with epidemic potential as measures are lifted in the short term. Whether the significant societal and behavioural changes that have occurred during the pandemic will lead to a reduction in transmission of infectious diseases, such as influenza and norovirus, remains to be seen.

Funding sources

None to declare.

Conflict of interest statement

No conflict of interest to declare.
  3 in total

1.  Impact of COVID-19 on national surveillance of norovirus in England and potential risk of increased disease activity in 2021.

Authors:  A Douglas; F G Sandmann; D J Allen; C C Celma; S Beard; L Larkin
Journal:  J Hosp Infect       Date:  2021-03-11       Impact factor: 3.926

Review 2.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

3.  Decrease in norovirus infections in Germany following COVID-19 containment measures.

Authors:  Ulrich Eigner; Thomas Verstraeten; John Weil
Journal:  J Infect       Date:  2021-02-10       Impact factor: 6.072

  3 in total
  2 in total

1.  Norovirus outbreak amid COVID-19 in the United Kingdom; priorities for achieving control.

Authors:  Farah Yasmin; Syed Hasan Ali; Irfan Ullah
Journal:  J Med Virol       Date:  2021-11-09       Impact factor: 20.693

2.  Assessment of Food and Waterborne Viral Outbreaks by Using Field Epidemiologic, Modern Laboratory and Statistical Methods-Lessons Learnt from Seven Major Norovirus Outbreaks in Finland.

Authors:  Aleksandra Polkowska; Sirpa Räsänen; Pekka Nuorti; Leena Maunula; Katri Jalava
Journal:  Pathogens       Date:  2021-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.